There are big shows, and then there are big shows to ME.
I’ve seen Tool a couple of times in the years since — in Cincinnati and Toledo — but I haven’t seen the incredibly brilliant art-metal band play album from a then-new album since their show on Sept. 25, 2006.
That all changes when Tool — which just released its first album in what felt like 10,000 days since 2006’s “10,000 Days,” the better-by-the-listen “Fear Inoculum” — plays Cleveland’s Rocket Mortgage FieldHouse Nov. 6.
Some background on recent history, including their entry into the streaming-music world, via a news release from event promoter Live Nation:
Fear Inoculum’s release caps off over a decade of speculation and anticipation, with confirmation of the release arriving in May as the band flashed “August 30” from the
stage as they performed two new songs: “Descending” and “Invincible.”
As August arrived, TOOL released their back catalog via digital service providers,
seeing Opiate, Undertow, Ænima, Lateralus and 10,000 Days rack up in excess of 20
million streams in the subsequent 48 hours and occupy the top five spots on iTunes’
Top 10 Album Charts. 23 years after its initial release, Ænima re-entered Billboard’s
Top 200, arriving at #10, with Lateralus (#16), 10,000 Days (#18) and Undertow (#19)
landing in the Top 20. TOOL’s debut release, 1992’s Opiate EP, made its Billboard
chart premiere, arrived at #59. The band also broke records that week: taking four of the top five spots on Billboard’s Hard Rock Albums chart (the first act to achieve that feat upon digital release) and claiming 15 (of 25) spots on Billboard’s Rock Digital Song Sales chart.
While I like the title track, the early standouts from the album are “Pneuma” and “7empest,” both epic rock experiences.
While a ticket presale for the coming tour for the members of the Tool Army happens Sept. 4, everyone else has to wait until Sept. 6. Tickets start at $55 and go up to about $150.
Mark Meszoros thinks there is no more finely crafted rock song than Tool’s “Lateralus.” Follow him on Twitter @MarkMeszoros.